Mirador Therapeutics Inc., a next-generation precision medicine company focused on developing first-in-class or best-in-class therapeutics for immunology and inflammation (I&I), has appointed Gregg Gilbert as chief financial officer.   Gilbert brings more than 25 years of leadership experience in biopharma equity research analysis and investment banking to the role.   “Since launching earlier this year with over $400 million in capital, the Mirador team has been focused on rapidly buildi...